Content area

Abstract

Background

Immune Checkpoint Inhibitor-related Pneumonitis (CIP) exhibits high morbidity and mortality rates in the real world, often coexisting with pneumonia, particularly after immunochemotherapy. We aimed to develop and validate a non-invasive nomogram for differentiating CIP from pneumonia in patients undergoing immunochemotherapy.

Methods

This study encompassed 237 patients from three hospitals. A multivariate logistic regression analysis was conducted to identify risk factors for CIP. Utilizing the random forest machine learning method, optimal development and validation cohort allocation ratios (in a ratio of 8:2) were determined for the predictive model. The performance of the nomogram was evaluated using calibration, the area under the receiver operating characteristic curve (AUC), and decision curve analysis (DCA). Subsequently respiratory pathogens, management, and outcomes were compared between CIP and No CIP cases.

Results

Among the 237 patients, 104 were diagnosed with CIP, and 133 were no CIP but pneumonia(No CIP). Smoking status, prior chronic obstructive pulmonary disease (COPD), ground glass opacities, non-specific interstitial pneumonitis, Neutrophil to Lymphocyte Ratio (NLR), pleural effusions, and Oxygen Partial Pressure (PaO2) emerged as non-invasive independent predictors of CIP. The nomogram exhibited good discrimination for both the development and validation cohorts, with AUC values of 0.817 (95% CI, 0.754–0.879) and 0.913 (95% CI, 0.826–0.999), respectively. The calibration curves demonstrated good fit for both the development and validation cohort, as evidenced by the Hosmer-Lemeshow tests (χ² = 3.939, p = 0.863 and χ² = 8.117, p = 0.422, respectively). DCA further highlighted their clinical utility. In CIP patients, the use of gamma globulin/albumin and glucocorticoids was significantly higher than in No CIP patients (39.4% vs 23.3%, p = 0.007; 79.8% vs 12.8%, p < 0.0001, respectively). The proportion of patients requiring mechanical ventilation was also significantly higher in the CIP compared to the No CIP group (21.2% vs 11.3%, p = 0.038).

Conclusion

The nomogram offers a non-invasive approach to differentiate CIP from pneumonia associated with immunochemotherapy, potentially facilitating early intervention and informed treatment decisions.

Details

1009240
Business indexing term
Title
Development and validation of a nomogram for differentiating immune checkpoint inhibitor-related pneumonitis from pneumonia in patients undergoing immunochemotherapy: a multicenter, real-world, retrospective study
Author
Duan, Linli 1 ; Liu, Guanglu 2 ; Huang, Zijie 3 ; Chen, Rong 1 ; Mo, Di 1 ; Xia, Yuxiao 1 ; Hu, Jiazhu 4 ; He, Mengzhang 1 

 Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China 
 Algorithm Development Department 1, GRGBanking Equipment Company Ltd., Guangzhou, China 
 Thoracic Surgery Department, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China 
 Department of Oncology, The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, China 
Publication title
Volume
16
First page
1495450
Number of pages
14
Publication year
2025
Publication date
May 2025
Section
Cancer Immunity and Immunotherapy
Publisher
Frontiers Media SA
Place of publication
Lausanne
Country of publication
Switzerland
Publication subject
e-ISSN
16643224
Source type
Scholarly Journal
Language of publication
English
Document type
Journal Article
Publication history
 
 
Online publication date
2025-05-19
Milestone dates
2024-09-12 (Recieved); 2025-04-29 (Accepted)
Publication history
 
 
   First posting date
19 May 2025
ProQuest document ID
3278313742
Document URL
https://www.proquest.com/scholarly-journals/development-validation-nomogram-differentiating/docview/3278313742/se-2?accountid=208611
Copyright
© 2025. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2025-12-19
Database
ProQuest One Academic